UroToday - Overactive Bladder (OAB)

Home

Overactive Bladder (OAB)

Overactive Bladder

UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.

Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Display

results per page

Results 541 - 555 of 671

<< Start < Prev 31 32 33 34 35 36 37 38 39 40 Next > End >>

Pelvic Floor Disorders, Diabetes, and Obesity in Women: Findings from the Kaiser Permanente Continence Associated Risk Epidemiology Study – Abstract
Monday, 22 October 2007
Department of Research and Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena CA 91101, USA
read more

Randomized, Double-Blind, Placebo- and Propiverine-Controlled Trial of the Once-Daily Antimuscarinic Agent Solifenacin in Japanese Patients with Overactive Bladder – Abstract
Monday, 22 October 2007
Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. yamaosa@cc.fmu.ac.jp
read more

Adsorptive Stripping Voltammetric Behavior and Determination of Anticholinergic Agent Oxybutynin Chloride on a Mercury Electrode - Abstract
Friday, 19 October 2007
School of Studies in Chemistry, Jiwaji University, Gwalior 474011, India
read more

A Population-Based Study of Urinary Symptoms and Incontinence: the Canadian Urinary Bladder Survey - Abstract
Thursday, 18 October 2007
Division of Urology, University of Toronto, Toronto, Ontario, Canada.
read more

Influence of Intravesical Potassium on Pelvic Floor Activity in Women with Overactive Bladder Syndrome: Comparative Urodynamics Might Provide Better Detection of Dysfunctional Voiding - Abstract
Wednesday, 17 October 2007
Department of Urology, Medical University Innsbruck, Austria
read more

Sublingual Oxybutynin Reduces Postoperative Pain Related to Indwelling Bladder Catheter after Radical Retropubic Prostatectomy - Abstract
Tuesday, 16 October 2007
DAR III, Hôpital Pellegrin-Tondu Bordeaux, Place Amélie Raba-Léon, 33076 Bordeaux cedex, France
read more

Cross-Cultural Differences for Adapting Overactive Bladder Symptoms: Results of an Epidemiologic Survey in Korea - Abstract
Monday, 15 October 2007
Department of Urology, University of Ulsan College of Medicine, Seoul, South Korea
read more

Percutaneous Tibial Nerve Stimulation: the Urgent PC((R)) Device - Abstract
Friday, 12 October 2007
Rijnstate Hospital, Department of Urology, PO Box 9555, NL-6800 TA, Arnhem, The Netherlands. mvanbalken@alysis.nl
read more

How to Choose the Initial Drug Treatment for Overactive Bladder - Abstract
Thursday, 11 October 2007
Alliance Urology Specialists, Bladder Control and Pelvic Pain Center, 509 N. Elam Avenue, Greensboro, NC 27403, USA. smacdiarmid@allianceurology.com
read more

Efficacy of Tolterodine in Women with Detrusor Overactivity and Anterior Vaginal Wall Prolapse: Is It the Same? - Abstract
Wednesday, 10 October 2007
Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy
read more

Repeated Botulinum Toxin Injection for Idiopathic Overactive Bladder: Will Chemodenervation become a Long-Term Solution? - Abstract
Tuesday, 09 October 2007
read more

Long-Term Darifenacin Treatment for Overactive Bladder in Patients Aged 65 Years and Older: Analysis of Results from a 2-Year, Open-Label Extension Study - Abstract
Monday, 08 October 2007
Jewish General Hospital, McGill University, Montréal, Canada, Welborn Clinic, Evansville, IN, USA, Department of Gynaecology and Obstetrics, Aalborg Hospital, Aalborg, Denmark, Mercy Hospital for Women, Melbourne, Australia, Novartis Pharma AG, Basel, Switzerland, and Department of Urology, University of Virginia School of Medicine, Charlottesville, VA, USA
read more

Does the Tension-Free Vaginal Tape Procedure (TVT) Affect the Voiding Function Over Time? Pressure-Flow Studies 1 Year and 3(1/2) Years after TVT - Abstract
Wednesday, 03 October 2007
Department of Obstetrics and Gynaecology, Glostrup County Hospital, University of Copenhagen, Glostrup, Denmark
read more

Urgency Assessment in the Evaluation of Overactive Bladder (OAB) - Abstract
Tuesday, 02 October 2007
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
read more

Prophylactic Antibiotics in Urodynamics: A Systematic Review of Effectiveness and Safety - Abstract
Monday, 01 October 2007
Department of Obstetrics and Gynaecology, Birmingham Women's Health Care NHS Trust, Edgbaston, Birmingham, UK.
read more

Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.

Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy

World Continence Week 2009

Patient Guide - Controlling Your Bladder Symptoms

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Promoting Continence Worldwide

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Urinary Incontinence: Epidemiology and Disease Burden
- Prepared by Alan J. Wein, MD, PhD (hon)

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment
- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity
- by Marcus Drake, MD

Two Types of Urgency
- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity
- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity
- by Philip M. Hanno, MD, MPH

Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review
- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder
- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
- by Ulrich Schwantes, PhD, et al.

The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise

A Review of Adherence to Drug Therapy in Patients with Overactive Bladder

Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release
- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery
- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder
- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder
- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome
- by Ling-Hong Tseng, MD, et al.

The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder
- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting
- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium
- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series

- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)

Drug Treatment - Committee Meeting Highlights

- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights

- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality

- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder
- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008
- Session Abstracts, Overactive Bladder